Skip to main content
Home
Latest news
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH

Type 1 diabetes: Medications

Highlights

03-14-2018 | Physical activity | Highlight | News

Physical activity beneficial in new-onset type 1 diabetes

Results of an observational study suggest that doing exercise around the time of type 1 diabetes diagnosis could extend the “honeymoon” period of low insulin requirement.

Editorial Board member Jay Shubrook follows up with treatment individualization specialist David Strain on the treatment challenges presented by older adults, and the implications for tailoring hypertension therapy in this diverse population (11:08).



Learning points include:

  • The rationale for emphasizing quality over quantity of life in certain subsets of the elderly patient population.
  • The importance of incorporating understanding of key comorbidities into treatment planning, including:
    • Left ventricular and/or diastolic dysfunction
    • Chronic kidney disease 
    • Benign prostatic hyperplasia
    • Heart failure
  • Single/multi-agent therapies capable of targeting hypertension and its comorbidities.
  • The importance of early renal function testing in older adults initiated on treatments for hypertension and its comorbidities.
  • Understanding renal impairment risks in vulnerable adults treated with angiotensin-converting-enzyme (ACE) inhibitors in patients.
  • Understanding the relative risk of hyponatremia with generally well-tolerated treatments like as thiazide diuretics.
  • Best practice for avoiding adverse drug events in the acute setting.
  • The challenges associated with treating concomitant heart failure in older adults.

« Video 4: Individualization of diabetes treatment: Considerations for frail, elderly patients with heart failure

Editorial Board member Jay Shubrook and Advisory Board member Robert Chilton get together once more to discuss best practice tips for identifying and treating hypertension in patients with pre-existing diabetes (12:17).



Learning points include:

  • Strategies to avoid common pitfalls when performing blood pressure measurements.
  • The importance of the blood pressure measurements in determining the risk of cardiovascular events.
  • The benefits of dual-action and preload-targeted therapies in hypertensive patients.
  • Why potassium levels are an important factor to consider before initiating treatment.

« Video 2: Why aren't we reaching blood pressure goals, despite the raised target?



Video 4: Individualization of diabetes treatment: Considerations for frail, elderly patients with heart failure »

01-16-2018 | Type 1 diabetes | Editorial | Article

Sodium-glucose cotransporter-2 inhibitors for type 1 diabetes: Ready for prime time?

Editorial board member John Wilding casts a critical eye over the positive buzz surrounding the potential uses of sodium-glucose cotransporter 2 inhibitors in type 1 diabetes treatment.

12-08-2017 | Diagnosis | Case report | Article

A case of maturity onset diabetes of the young (MODY3) in a family with a novel HNF1A gene mutation in five generations

Ovsyannikova AK et al. Diabetes Ther 2018; 9: 413. doi: 10.1007/s13300-017-0350-8

11-08-2017 | Long-acting insulins | Editorial | Article

Longer-acting basal insulin analogs: What, how, why, when, and who?

Advisory Board member and pharmacist, Josh Neumiller, presents a practical guide to support clinical decision-making in the initiation and titration of U300 insulin glargine and insulin degludec.

Previous
Image Credits